For the period of 15 to 21 October 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 15 – 21 October 2022 Document Preview:
UK NICE International Knowledge Exchange on Guideline Development
Representatives of the Health Technology Assessment Division (HTAD) headed by Director Anna Melissa Guerrero attended the knowledge exchange session with the United Kingdom’s National Health Service Consortium for Global Health (NHSC) – represented by the National Institute of Health and Care Excellence (NICE) on 18-19 October 2022 held in The Peninsula Hotel, Makati City. Participants continue reading : UK NICE International Knowledge Exchange on Guideline Development
HTAC Recommendation on COVID-19 Moderna for children 6 to 11 years old
Date of publication: 22 July 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Moderna for children 6 to continue reading : HTAC Recommendation on COVID-19 Moderna for children 6 to 11 years old
HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)
On 19 October 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of zoledronic acid (4mg/5mL concentrated solution for IV infusion) for the treatment of patients with malignancy-related bone disease through its inclusion in the PNF. In developing its recommendation for zoledronic acid, the HTAC considered the following: Details of continue reading : HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)